Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 6/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562449 | 0.81 | TLR7 (0.40) | CNR2MAPT | |
| SCHEMBL562152 | 0.81 | TP53 (0.35) | CNR2MAPT | |
| SCHEMBL562921 | 0.81 | KCNH2 (0.41) | KMT2AMEN1MAPT | |
| SCHEMBL3339558 | 0.80 | SLC2A1 (0.42) | KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL562893 | 0.78 | BRD4 (0.40) | DYRK1ABRD4KMT2AGLAKDM4E | |
| SCHEMBL563383 | 0.78 | TLR7 (0.45) | KMT2AALDH1A1MAPT | |
| SCHEMBL563646 | 0.76 | KDM4E (0.39) | DYRK1ABRD4KMT2AMEN1ALDH1A1 | |
| SCHEMBL561914 | 0.75 | TLR7 (0.39) | KMT2AMEN1ALDH1A1KDM4ERAB9A | |
| SCHEMBL562256 | 0.75 | KCNH2 (0.37) | CNR2 | |
| SCHEMBL563162 | 0.72 | PTGS2 (0.33) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. | 2010-06-17 | — | — | US | disclosed |
| EP-1924581-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | Pfizer, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007028129-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | PFIZER INC. (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152230-A1 | HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS | IL4, IL2, IL4I1 | DYRK1A 4409/4885BRD4 193/4885MTNR1A 1306/4885 |
| US-20120035209-A1 | Hydroxy Substituted 1H-Imidazopyridines and Methods | IL2, IL4, IL4I1 | DYRK1A 4469/4885BRD4 224/4885MTNR1A 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.